A Phase 1/1b Study of IAM1363 in HER2 Cancers

Clinical trial NCT06253871 · RECRUITING

Trial details

NCT number: NCT06253871
Sponsor: Iambic Therapeutics, Inc
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

HER2 Mutation-Related Tumors HER2 HER2-positive Breast Cancer HER2 + Breast Cancer Brain Metastases From Solid Tumors Brain Metastases From HER2 and Breast Cancer CNS Metastases HER2-Positive Solid Tumors NSCLC (Non-small Cell Lung Cancer)HER2-positive Bladder Cancer HER2-positive Colorectal Cancer HER2 + Gastric Cancer

Start date: 2024-03-25
Primary completion: 2027-12-01
Enrollment: 383

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.